Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Relay Therapeutics ( (RLAY) ) has issued an announcement.
On February 3, 2026, Relay Therapeutics announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its lead drug candidate zovegalisib (RLY-2608), in combination with fulvestrant, for adults with PIK3CA-mutant HR+/HER2- locally advanced or metastatic breast cancer whose disease has recurred or progressed after CDK4/6 inhibitor treatment. The designation, based on robust Phase 1/2 data from the ReDiscover trial across multiple PIK3CA mutations and dosing regimens, underscores zovegalisib’s potential to address a large, underserved patient population that lacks pan-mutant selective PI3Kα inhibitor regimens and bolsters Relay Therapeutics’ position in precision oncology by validating its allosteric, isoform-selective approach to PI3Kα inhibition.
The most recent analyst rating on (RLAY) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
The score is primarily held back by weak financial performance—minimal revenue scale, large losses, and substantial ongoing cash burn—partially offset by a low-debt balance sheet. Technicals are mixed but somewhat supportive given the price remains above key longer-term moving averages, while valuation is constrained by negative earnings and no dividend yield.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage small molecule precision medicine company focused on developing therapies for cancer and genetic diseases using its Dynamo platform, which combines advanced computational and experimental tools to target previously intractable proteins. Its lead asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor in clinical development and is in a Phase 3 trial for HR+/HER2- metastatic breast cancer, while also being studied in PI3Kα-driven vascular anomalies alongside additional pipeline programs in NRAS-driven solid tumors and Fabry disease.
Average Trading Volume: 2,243,768
Technical Sentiment Signal: Buy
Current Market Cap: $1.33B
Learn more about RLAY stock on TipRanks’ Stock Analysis page.